Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Eplerenone can improve outcomes in mild CHF

By News team

Use of eplerenone for patients with mildly symptomatic congestive heart failure can reduce their risk of cardiovascular death and first admission to hospital for heart failure, say the authors of the EMPHASIS-HF study published in the New England Journal of Medicine (online 14 November 2010).

The study included 2,737 patients with New York Heart Association class II heart failure (ie, patients with mild symptoms) and a left-ventricular ejection fraction of 35% or less. Patients were randomised to receive eplerenone (up to 50mg daily) or placebo.

The primary outcome — a composite of cardiovascular death and first hospital admission for heart failure — occurred in 18.3% of patients taking eplerenone compared with 25.9% of patients taking placebo (hazard ratio 0.63; 95% confidence interval 0.54–0.74; P<0.001).

Helen Williams, consultant pharmacist for cardiovascular disease in South London, commented: “Before this study, data from the RALES study supported the use of spironolactone in severe chronic heart failure, namely NYHA class IV or NYHA class III with a recent class IV exacerbation [NEJM 1999;341:709]. The EPHESUS data supported the use of eplerenone in post-myocardial infarction heart failure [NEJM 2003;348:1309].”

She explained that EMPHASIS-HF was the first study to investigate the use of an aldosterone antagonist in mild-to-moderate heart failure. In this group of patients, treatment with eplerenone led to a 3% absolute reduction in the risk of death (P=0.008) and a 5.9% absolute reduction in the risk of hospital admission (P<0.001), compared with placebo.

Therapy was generally well tolerated, although treatment with eplerenone was associated with an increased risk of hyperkalaemia.

“EMPHASIS demonstrates that aldosterone antagonists can significantly improve outcomes in all patients with symptomatic chronic heart failure,” Ms Williams said. “This study will no doubt lead to debate as to whether the same outcome could be achieved using spironolactone, at much lower cost.”

NPC logo Does eplerenone have a role in mild heart failure?


Citation: Clinical Pharmacist URI: 11048887

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Mildly symptomatic congestive heart failure

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.